TRV GP Iv, LLC

In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), TRV GP Iv, LLC reported 2 stock positions worth $80.2 million. Its top holding was Tango Therapeutics (TNGX) at 65.0% of the portfolio, followed by Pliant Therapeutics (PLRX, 35.0%). Compared with Q3 2024, it sold out of 1. The biggest sale was an exit from Fulcrum Therapeutics (FULC).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001688325
Portfolio Value
$80.2M (Q4 2024)
SEC Filing
0000950123-25-002038 ↗ filed Feb 13, 2025

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $206.4M Q1 2024 Q2 2024: $202.2M Q2 2024 Q3 2024: $162.1M Q3 2024 Q4 2024: $80.2M $80.2M Q4 2024 Q1 2025: $92.9M Q1 2025 Q2 2025: $163.3M Q2 2025 Q3 2025: $274.0M Q3 2025 Q4 2025: $255.1M Q4 2025 Q1 2026: $266.9M Q1 2026 Q2 2026: $253.7M Q2 2026

Holdings 2 stocks · $80.2M
TNGX Tango Therapeutics Inc. 64.97% 16,859,075 $52.1M No change
PLRX Pliant Therapeutics Inc. 35.03% 2,132,867 $28.1M No change

Portfolio Sells Q3 2024 → Q4 2024
FULC Fulcrum Therapeutics Inc. Sold out 0.00% −5.16

Portfolio Buys Q3 2024 → Q4 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$253.7MMAZE, TNGX
Q1 2026 2$266.9MMAZE, TNGX
Q4 2025 2$255.1MMAZE, TNGX
Q3 2025 2$274.0MMAZE, TNGX
Q2 2025 3$163.3MTNGX, MAZE, PLRX
Q1 2025 3$92.9MMAZE, TNGX, PLRX
Q4 2024 2$80.2MTNGX, PLRX
Q3 2024 3$162.1MTNGX, PLRX, FULC
Q2 2024 3$202.2MTNGX, PLRX, FULC
Q1 2024 3$206.4MTNGX, PLRX, FULC